|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCNK |
Gene summary for CCNK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCNK | Gene ID | 8812 |
| Gene name | cyclin K | |
| Gene Alias | CPR4 | |
| Cytomap | 14q32.2 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | A0A024R6K1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8812 | CCNK | LZE2D | Human | Esophagus | HGIN | 2.39e-02 | 2.72e-01 | 0.0642 |
| 8812 | CCNK | LZE2T | Human | Esophagus | ESCC | 2.77e-03 | 8.05e-01 | 0.082 |
| 8812 | CCNK | LZE4T | Human | Esophagus | ESCC | 9.30e-20 | 5.90e-01 | 0.0811 |
| 8812 | CCNK | LZE5T | Human | Esophagus | ESCC | 1.14e-04 | 5.76e-01 | 0.0514 |
| 8812 | CCNK | LZE7T | Human | Esophagus | ESCC | 6.56e-06 | 2.39e-01 | 0.0667 |
| 8812 | CCNK | LZE8T | Human | Esophagus | ESCC | 8.98e-09 | 1.96e-01 | 0.067 |
| 8812 | CCNK | LZE20T | Human | Esophagus | ESCC | 1.48e-20 | 5.89e-01 | 0.0662 |
| 8812 | CCNK | LZE22D1 | Human | Esophagus | HGIN | 4.39e-03 | 2.13e-02 | 0.0595 |
| 8812 | CCNK | LZE22T | Human | Esophagus | ESCC | 3.92e-07 | 3.78e-01 | 0.068 |
| 8812 | CCNK | LZE24T | Human | Esophagus | ESCC | 2.07e-41 | 1.18e+00 | 0.0596 |
| 8812 | CCNK | LZE6T | Human | Esophagus | ESCC | 3.58e-07 | 1.06e-01 | 0.0845 |
| 8812 | CCNK | P1T-E | Human | Esophagus | ESCC | 2.81e-16 | 6.15e-01 | 0.0875 |
| 8812 | CCNK | P2T-E | Human | Esophagus | ESCC | 5.00e-27 | 3.90e-01 | 0.1177 |
| 8812 | CCNK | P4T-E | Human | Esophagus | ESCC | 1.45e-22 | 5.76e-01 | 0.1323 |
| 8812 | CCNK | P5T-E | Human | Esophagus | ESCC | 1.73e-17 | 3.82e-01 | 0.1327 |
| 8812 | CCNK | P8T-E | Human | Esophagus | ESCC | 3.89e-25 | 5.52e-01 | 0.0889 |
| 8812 | CCNK | P9T-E | Human | Esophagus | ESCC | 7.44e-17 | 3.08e-01 | 0.1131 |
| 8812 | CCNK | P10T-E | Human | Esophagus | ESCC | 7.91e-44 | 7.47e-01 | 0.116 |
| 8812 | CCNK | P11T-E | Human | Esophagus | ESCC | 1.36e-13 | 4.92e-01 | 0.1426 |
| 8812 | CCNK | P12T-E | Human | Esophagus | ESCC | 5.11e-47 | 8.58e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603227 | Esophagus | HGIN | viral process | 118/2587 | 415/18723 | 3.01e-15 | 6.22e-13 | 118 |
| GO:001905827 | Esophagus | HGIN | viral life cycle | 93/2587 | 317/18723 | 3.66e-13 | 5.63e-11 | 93 |
| GO:001907926 | Esophagus | HGIN | viral genome replication | 48/2587 | 131/18723 | 4.65e-11 | 5.07e-09 | 48 |
| GO:004440326 | Esophagus | HGIN | biological process involved in symbiotic interaction | 71/2587 | 290/18723 | 7.09e-07 | 3.00e-05 | 71 |
| GO:00063548 | Esophagus | HGIN | DNA-templated transcription, elongation | 27/2587 | 91/18723 | 6.62e-05 | 1.52e-03 | 27 |
| GO:00518518 | Esophagus | HGIN | modulation by host of symbiont process | 19/2587 | 60/18723 | 3.07e-04 | 5.15e-03 | 19 |
| GO:00447888 | Esophagus | HGIN | modulation by host of viral process | 12/2587 | 30/18723 | 3.62e-04 | 5.68e-03 | 12 |
| GO:00518177 | Esophagus | HGIN | modulation of process of other organism involved in symbiotic interaction | 23/2587 | 81/18723 | 4.52e-04 | 6.62e-03 | 23 |
| GO:00327866 | Esophagus | HGIN | positive regulation of DNA-templated transcription, elongation | 11/2587 | 27/18723 | 5.28e-04 | 7.56e-03 | 11 |
| GO:00358219 | Esophagus | HGIN | modulation of process of other organism | 27/2587 | 106/18723 | 9.89e-04 | 1.24e-02 | 27 |
| GO:00327844 | Esophagus | HGIN | regulation of DNA-templated transcription, elongation | 16/2587 | 53/18723 | 1.58e-03 | 1.79e-02 | 16 |
| GO:005170210 | Esophagus | HGIN | biological process involved in interaction with symbiont | 24/2587 | 94/18723 | 1.78e-03 | 1.92e-02 | 24 |
| GO:00448275 | Esophagus | HGIN | modulation by host of viral genome replication | 8/2587 | 19/18723 | 2.40e-03 | 2.41e-02 | 8 |
| GO:00708162 | Esophagus | HGIN | phosphorylation of RNA polymerase II C-terminal domain | 6/2587 | 12/18723 | 3.03e-03 | 2.88e-02 | 6 |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
| GO:0019079111 | Esophagus | ESCC | viral genome replication | 102/8552 | 131/18723 | 4.31e-14 | 2.19e-12 | 102 |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCNK | SNV | Missense_Mutation | rs867757117 | c.1360G>A | p.Glu454Lys | p.E454K | O75909 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| CCNK | SNV | Missense_Mutation | novel | c.986N>A | p.Ser329Tyr | p.S329Y | O75909 | protein_coding | deleterious(0) | benign(0.054) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCNK | SNV | Missense_Mutation | c.656N>G | p.Lys219Arg | p.K219R | O75909 | protein_coding | deleterious(0.04) | benign(0.348) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| CCNK | deletion | Frame_Shift_Del | c.209delN | p.Leu71TrpfsTer5 | p.L71Wfs*5 | O75909 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| CCNK | deletion | Frame_Shift_Del | novel | c.806delN | p.His271IlefsTer112 | p.H271Ifs*112 | O75909 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| CCNK | SNV | Missense_Mutation | c.1298N>G | p.Ser433Cys | p.S433C | O75909 | protein_coding | deleterious_low_confidence(0) | benign(0.339) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCNK | SNV | Missense_Mutation | novel | c.149N>C | p.Arg50Pro | p.R50P | O75909 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| CCNK | SNV | Missense_Mutation | novel | c.206N>T | p.Asp69Val | p.D69V | O75909 | protein_coding | tolerated(0.4) | possibly_damaging(0.584) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCNK | SNV | Missense_Mutation | c.568N>G | p.Asn190Asp | p.N190D | O75909 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCNK | SNV | Missense_Mutation | c.1606N>G | p.Pro536Ala | p.P536A | O75909 | protein_coding | deleterious_low_confidence(0.01) | benign(0.283) | TCGA-NH-A6GB-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8812 | CCNK | KINASE | fluorouracil | FLUOROURACIL | ||
| 8812 | CCNK | KINASE | epirubicin | EPIRUBICIN | ||
| 8812 | CCNK | KINASE | cyclophosphamide | CYCLOPHOSPHAMIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |